Source link : https://www.newshealth.biz/health-news/fda-approves-axatilimab-for-chronic-gvhd/
The US Food and Drug Administration (FDA) has approved axatilimab (Niktimvo, Incyte Corporation) for the treatment of adult and pediatric patients with chronic graft versus host disease (GVHD) who have not responded to at least two prior lines of systemic therapy and who weigh ≥ 40 kg. Chronic GVHD is a potentially life-threatening complication of […]
Author : News Health
Publish date : 2024-08-14 21:25:36
Copyright for syndicated content belongs to the linked Source.
Categories